In this issue of Blood, Byrd et al provide an important update on the prolonged ef ficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.

Forconi, F. (2015). Three years of ibrutinib in CLL. BLOOD, 125(16), 2455-2456 [10.1182/blood-2015-03-630772].

Three years of ibrutinib in CLL

FORCONI, FRANCESCO
2015-01-01

Abstract

In this issue of Blood, Byrd et al provide an important update on the prolonged ef ficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.
2015
Forconi, F. (2015). Three years of ibrutinib in CLL. BLOOD, 125(16), 2455-2456 [10.1182/blood-2015-03-630772].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/997795
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo